Skip Navigation

Celligenics, an associate company of Best World, partners with NTU and SRIS on developing new and affordable therapies for chronic wounds

Image courtesy of Celligenics

Celligenics, an associate company of Best World International, is partnering with scientists from Nanyang Technological University, Singapore (NTU Singapore) and the Skin Research Institute of Singapore (SRIS) to develop therapies that speed up healing for chronic wounds such as diabetic ulcers and bed sores.

Such chronic wounds, if left untreated, can lead to amputations or even death should bacteria enter the bloodstream. The project, which is awarded the Skin Innovation Grant, aims to trigger and expedite the healing process of the wound to prevent such outcomes.

Stimulate cell repair and speed up wound closure by 33%

A regenerative extract developed through Celligenics’ proprietary stem cell technology will be the foundation for the project’s prototype of wound healing patches, gels or sprays. The extract was found to be able to stimulate cell repair and speed up wound closure by 33%, affirming its potential in the development of these therapies.

We are hopeful that the tripartite collaboration will contribute to more affordable and accessible solutions for chronic wounds to the market.

Sources: Lianhe Zaobao, NTU/LKC School of Medicine, BioSpectrum Asia Edition, Mirage News

Celligenics and Best World Partnership

In 2019, Best World entered into a share subscription agreement with Celligenics, a biomedical start-up and A*STAR spin-off. Celligenics is a regenerative stem cell biotech company that develops breakthrough stem cell solutions to address some of today’s pressing lifestyle and clinical needs. The partnership also serves to strengthen the development of relevant cosmetic active ingredients for usage in Best World’s future products.

Back to all publications